Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 2/20 | 0.37 |
| ▸ | MGAM | O43451 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | SI | P14410 | 1/20 | 0.35 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | NAAA | Q02083 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19460464 | 0.85 | DUT (0.39) | DUT | |
| SCHEMBL3799853 | 0.84 | DUT (0.39) | DUTMGAMGAASIMGAM2 | |
| SCHEMBL19460463 | 0.83 | DUT (0.38) | DUT | |
| SCHEMBL21121956 | 0.82 | EPHX1 (0.49) | DUT | |
| SCHEMBL17211882 | 0.82 | TSHR (0.51) | DUTTDP1POLBTSHR | |
| SCHEMBL13320016 | 0.82 | MGAM (0.33) | DUTMGAMGAASIMGAM2 | |
| SCHEMBL23067127 | 0.81 | LMNA (0.38) | DUTTSHR | |
| SCHEMBL19543597 | 0.81 | DUT (0.37) | DUT | |
| SCHEMBL28538333 | 0.79 | DUT (0.43) | DUT | |
| SCHEMBL16696044 | 0.79 | ALDH1A1 (0.47) | DUTGAATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030027870-A1 | Fullerene derivatives that modulate nitric oxide synthase and clamodulin activity | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030027870-A1 | Fullerene derivatives that modulate nitric oxide synthase and clamodulin activity | NOS1, NOS2, NOS3 | DUT 3314/4885MGAM 3728/4885GAA 3627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.